Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience has announced an increase in its share capital following the exercise of a right to convert debt into shares. The issuance of 170,000 new shares at a subscription price of NOK 3 per share will raise the company’s share capital to NOK 2,685,934. This move is expected to strengthen the company’s financial position and support its ongoing development projects, including the novel drug candidate HRO350.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company that develops and commercializes pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is working on HRO350, an oral drug candidate for treating mild-to-moderate psoriasis, and sells nutraceuticals globally under the ROMEGA® brand.
Average Trading Volume: 88,727
Current Market Cap: NOK90.74M
For an in-depth examination of 9TD stock, go to TipRanks’ Stock Analysis page.